Akebia Therapeutics Competitors

Morphic (NASDAQ:MORF) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

61.5% of Morphic shares are held by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are held by institutional investors. 39.5% of Morphic shares are held by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Morphic and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Morphic has higher earnings, but lower revenue than Akebia Therapeutics. Morphic is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Morphic has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Morphic and Akebia Therapeutics, as reported by MarketBeat.

Morphic presently has a consensus target price of $63.3333, indicating a potential upside of 14.98%. Akebia Therapeutics has a consensus target price of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Morphic.

Profitability

This table compares Morphic and Akebia Therapeutics' net margins, return on equity and return on assets.

Pandion Therapeutics (NASDAQ:PAND) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Valuation and Earnings

This table compares Pandion Therapeutics and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Pandion Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics.

Insider and Institutional Ownership

35.7% of Pandion Therapeutics shares are held by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are held by institutional investors. 2.6% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Pandion Therapeutics and Akebia Therapeutics, as reported by MarketBeat.

Pandion Therapeutics presently has a consensus target price of $44.25, indicating a potential downside of 26.31%. Akebia Therapeutics has a consensus target price of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Pandion Therapeutics.

Profitability

This table compares Pandion Therapeutics and Akebia Therapeutics' net margins, return on equity and return on assets.

Five Prime Therapeutics (NASDAQ:FPRX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Valuation & Earnings

This table compares Five Prime Therapeutics and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Five Prime Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.3% of Five Prime Therapeutics shares are owned by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Five Prime Therapeutics and Akebia Therapeutics, as reported by MarketBeat.com.

Five Prime Therapeutics currently has a consensus price target of $30.7143, indicating a potential downside of 19.17%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Five Prime Therapeutics.

Profitability

This table compares Five Prime Therapeutics and Akebia Therapeutics' net margins, return on equity and return on assets.

Summary

Akebia Therapeutics beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Cytokinetics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Valuation & Earnings

This table compares Cytokinetics and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Cytokinetics has higher earnings, but lower revenue than Akebia Therapeutics. Cytokinetics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cytokinetics and Akebia Therapeutics, as reported by MarketBeat.com.

Cytokinetics currently has a consensus price target of $33.6364, indicating a potential upside of 36.18%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Cytokinetics.

Profitability

This table compares Cytokinetics and Akebia Therapeutics' net margins, return on equity and return on assets.

Summary

Akebia Therapeutics beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Valuation & Earnings

This table compares Amneal Pharmaceuticals and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Akebia Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amneal Pharmaceuticals and Akebia Therapeutics, as reported by MarketBeat.com.

Amneal Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 18.85%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Amneal Pharmaceuticals.

Profitability

This table compares Amneal Pharmaceuticals and Akebia Therapeutics' net margins, return on equity and return on assets.

Summary

Amneal Pharmaceuticals beats Akebia Therapeutics on 8 of the 13 factors compared between the two stocks.

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Ironwood Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Ironwood Pharmaceuticals and Akebia Therapeutics, as reported by MarketBeat.com.

Ironwood Pharmaceuticals currently has a consensus price target of $11.40, indicating a potential upside of 7.45%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Ironwood Pharmaceuticals.

Insider & Institutional Ownership

69.0% of Akebia Therapeutics shares are owned by institutional investors. 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Ironwood Pharmaceuticals and Akebia Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ironwood Pharmaceuticals and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Ironwood Pharmaceuticals has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.